Education
About Us
Working with TipRanks
Follow Us
Cyclerion Therapeutics,Inc. (CYCN)
:CYCN
RESEARCH TOOLSreports
Total Valuation
Cyclerion Therapeutics has a market cap or net worth of $9.79M. The enterprise value is $6.57M.
Market Cap$9.79M
Enterprise Value$6.57M
Share Statistics
Cyclerion Therapeutics has 3,210,094 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,210,094
Owned by Insiders21.50%
Owned by Institutions8.76%
Financial Efficiency
Cyclerion Therapeutics’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -40.99%.
Return on Equity (ROE)-0.35
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-40.99%
Return on Capital Employed (ROCE)-0.41
Revenue Per Employee2.00M
Profits Per Employee-3.06M
Employee Count1
Asset Turnover0.21
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio0.96
Price to Fair Value0.92
Price to FCF-3.07
Price to Operating Cash Flow-2.45
PEG Ratio-0.58
Income Statement
In the last 12 months, Cyclerion Therapeutics had revenue of 2.00M and earned -3.06M in profits. Earnings per share was -1.21.
Revenue2.00M
Gross Profit2.00M
Operating Income-3.63M
Pretax Income-3.06M
Net Income-3.06M
EBITDA-3.63M
Earnings Per Share (EPS)-1.21
Cash Flow
In the last 12 months, operating cash flow was -3.43M and capital expenditures 0.00, giving a free cash flow of -3.43M billion.
Operating Cash Flow-3.43M
Free Cash Flow-3.43M
Free Cash Flow per Share-1.07
Dividends & Yields
Cyclerion Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.57
52-Week Price Change-8.76%
50-Day Moving Average3.11
200-Day Moving Average2.93
Relative Strength Index (RSI)45.94
Average Volume (3m)27.88K
Important Dates
Cyclerion Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Cyclerion Therapeutics as a current ratio of 5.83, with Debt / Equity ratio of 0.00%
Current Ratio5.83
Quick Ratio5.83
Debt to Market Cap0.00
Net Debt to EBITDA0.89
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cyclerion Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cyclerion Therapeutics EV to EBITDA ratio is -1.34, with an EV/FCF ratio of -1.13.
EV to Sales2.44
EV to EBITDA-1.34
EV to Free Cash Flow-1.13
EV to Operating Cash Flow-1.13
Balance Sheet
Cyclerion Therapeutics has $3.64M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$3.64M billion.
Cash & Marketable Securities$3.64M
Total Debt$0.00
Net Cash-$3.64M
Net Cash Per Share-$1.13
Tangible Book Value Per Share$3.51
Margins
Gross margin is 96.11%, with operating margin of -181.40%, and net profit margin of -152.85%.
Gross Margin96.11%
Operating Margin-181.40%
Pretax Margin-152.85%
Net Profit Margin-152.85%
EBITDA Margin-181.40%
EBIT Margin-181.40%
Analyst Forecast
The average price target for Cyclerion Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast86.52%